I read all the 9 points multiple times, I really can’t think beyond a single point and that is Respiri, it’s performance, plans to make real impact in sales, making SP go back to respectable status. And open for all the discussion regarding the same.
Future market and plans aren’t that easy looking to me based on performance in home ground which was well known to the promoters and so many pharmacies were made to agree to support sales.
neither eBay, Cipla or pharmacies could bring value to the announcements. And on the top AFL, celebrity brand ambassador and activities sounds like not less than best effort with complete rejection from the market.
I neither support nor get into comparative talks as others as doing with ADR as every company has to perform on its own. But as investor we are worried about respiri and the rainbow we were shown as canvas of colours.
I respect only one thing and it’s performance that makes the impact visible and result that supports the claims made in multiple months by several activities in Australia.
- Forums
- ASX - By Stock
- RSH
- Ann: ADR: Letter to Shareholders re takeover offer
Ann: ADR: Letter to Shareholders re takeover offer, page-32
Featured News
Add RSH (ASX) to my watchlist
(20min delay)
|
|||||
Last
9.1¢ |
Change
0.008(9.64%) |
Mkt cap ! $117.4M |
Open | High | Low | Value | Volume |
8.1¢ | 9.1¢ | 8.1¢ | $226.2K | 2.562M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 200000 | 9.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.1¢ | 297354 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 200000 | 0.090 |
1 | 100000 | 0.084 |
1 | 147499 | 0.081 |
3 | 101350 | 0.080 |
1 | 500000 | 0.079 |
Price($) | Vol. | No. |
---|---|---|
0.091 | 297354 | 1 |
0.092 | 15000 | 1 |
0.094 | 16931 | 1 |
0.095 | 743460 | 2 |
0.098 | 545929 | 3 |
Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
Featured News
RSH (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online